DigestAID

DigestAID is a Portuguese medical artificial-intelligence company based in Porto that develops deep-learning software for endoscopy and diagnostic support across digestive healthcare, gynecology and pulmonology. According to its official website, the company positions itself as building "cutting-edge AI technologies ready to change the landscape in digestive healthcare, gynecology and pulmonology — from real-time detection to diagnostic support, helping clinicians see more and decide with confidence." Its stated mission is to "drive innovation in healthcare" by building and implementing end-to-end AI solutions across multiple clinical and surgical fields. The company's core offering is an integrated AI platform, described on its products page as an "Application Ecosystem" extending across multiple clinical specialties and procedures. The platform covers GI & Hepatobiliary applications (including EUS, cholangioscopy, capsule endoscopy, digestive motility and enteroscopy), gynecology (colposcopy and hysteroscopy), pulmonology (bronchoscopy) and surgical & interventional procedures (laparoscopy, coloproctology, EUS and anal HRA). Specific products include AI-assisted analysis for capsule endoscopy, colon capsule and device-assisted enteroscopy, as well as pancreatobiliary intelligence for cholangioscopy and endoscopic ultrasound. The company states that its capsule-endoscopy technologies are CE marked in accordance with applicable European Union medical device requirements and FDA 510(k) cleared. DigestAID emphasizes the scale of its clinical data and scientific output. Its website claims an "extensive, heterogeneous and diverse dataset with over 10 million exams from world-renowned institutions," patent-protected AI technologies, and "500+ publications." It also states that its solutions are developed "in partnership with leading care institutions and KOLs" (key opinion leaders), and that it works with world-leading healthcare institutions. The company describes its team as combining "the enthusiasm and expertise of young and senior medical doctors and engineers, continuously working to raise the bar in GI, gynecological, and respiratory endoscopy." Leadership is publicly associated with Miguel Mascarenhas, identified on the company's About page as CEO, MD, PhD, with a background in Gastroenterology. The company maintains a presence on LinkedIn for updates. It is a private company; no parent company, owner or stock listing is indicated in the available evidence. Its headquarters location in Porto, Portugal is corroborated by Wikidata, which describes it as a "company in Porto, Portugal."

DigestAID is a Portuguese medical artificial-intelligence company headquartered in Porto, Portugal. Public evidence about its founding date and founders is limited; Wikidata describes it simply as a "company in Porto, Portugal," and the company's own website does not state a founding year in the supplied material. What is clear from its official communications is that it was established to apply deep-learning AI to endoscopy and diagnostic support in digestive healthcare, gynecology and pulmonology. The company's stated purpose is to "drive innovation in healthcare," with innovation directed at improving patients' lives described as its driving force. It builds and implements end-to-end AI solutions across multiple clinical and surgical fields. Its About page frames the company's work around three goals: improving diagnostic performance by overcoming the diagnostic limitations of current clinical methods; embracing innovation to support a wiser and more proficient clinical practice; and delivering valuable, cost-effective solutions that spare time and resources. DigestAID's development model is explicitly collaborative. The company states that its AI solutions are developed "in partnership with leading care institutions and KOLs" and that its work brings together clinical data, award-winning AI solutions, scientific research and partnerships with leading healthcare institutions. It claims an extensive, heterogeneous and diverse dataset with over 10 million exams from world-renowned institutions, patent-protected AI technologies, and 500+ publications. It also describes its team as combining the enthusiasm and expertise of young and senior medical doctors and engineers continuously working to raise the bar in GI, gynecological and respiratory endoscopy. Product-wise, DigestAID has built an integrated AI platform — described as an "Application Ecosystem" — extending across multiple clinical specialties and procedures. The platform spans GI & Hepatobiliary (EUS, cholangioscopy, capsule endoscopy, digestive motility, enteroscopy), gynecology (colposcopy, hysteroscopy), pulmonology (bronchoscopy) and surgical & interventional applications (laparoscopy, coloproctology, EUS, anal HRA). Specific AI products identify and differentiate normal mucosa and small-bowel lesions in capsule-endoscopy videos; identify colon polyps and precursor lesions in capsule-colonoscopy videos; detect ulcers and erosions in capsule-endoscopy exams to support objective inflammatory-bowel-disease assessment; detect lesions throughout the gastrointestinal tract in device-assisted enteroscopy; differentiate benign and malignant biliary strictures in cholangioscopy; and identify and differentiate cystic and solid pancreatic lesions during endoscopic ultrasound. The company states that its capsule-endoscopy technologies are CE marked in accordance with applicable European Union medical device requirements and FDA 510(k) cleared. Leadership is publicly associated with Miguel Mascarenhas, identified as CEO, MD, PhD, with a background in Gastroenterology. The company maintains a LinkedIn presence for updates on its AI technologies. No parent company, owner, acquisition history or stock listing is indicated in the available evidence, and the company appears to operate as a private entity.

Developer of patent-protected, clinically validated deep-learning solutions for digestive healthcare, gynecology and pulmonology, built in partnership with leading care institutions and KOLs.

• Capsule endoscopy AI

  Identifies and differentiates normal mucosa and small-bowel lesions in previously acquired capsule-endoscopy videos. CE marked and FDA 510(k) cleared.

• Colon capsule AI

  Identifies colon polyps and precursor lesions in capsule-colonoscopy videos.

• Capsule endoscopy ulcer/erosion detection

  Detects ulcers and erosions in capsule-endoscopy exams, supporting objective inflammatory-bowel-disease assessment.

• Device-assisted enteroscopy AI

  Detects lesions throughout the gastrointestinal tract in device-assisted enteroscopy.

• Cholangioscopy biliary stricture differentiation

  Differentiates benign and malignant biliary strictures in live and previously acquired cholangioscopy.

• EUS cystic pancreatic lesion identification

  Identifies and differentiates cystic pancreatic lesions during endoscopic ultrasound.

• EUS solid pancreatic lesion identification

  Identifies and differentiates solid pancreatic lesions during endoscopy.

1. 1DigestAID – Digestive Artificial Intelligence Developmentdigestaid.health
2. 2About us – DigestAIDdigestaid.health
3. 3Products – DigestAIDdigestaid.health
4. 4DIGESTAID (Portugal) – Wikidatawikidata.org